Aberdeen Group
LUCD icon

Aberdeen Group’s Lucid Diagnostics LUCD Stock Holding History

Aberdeen Group’s Portfolio LUCD Stock Details LUCD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$4.19M Buy
3,644,277
+186,383
+5% +$237K 0.01% 707
2025
Q4 		$3.77M Buy
3,457,894
+957,894
+38% +$1.07M 0.01% 726
2025
Q3 		$2.52M Buy
+2,500,000
New +$2.73M ﹤0.01% 761

Other funds holding LUCD

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
MCM
Masters Capital Management Atlanta, Georgia $3.03B AUM 57.21% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $93.1B AUM 28.26% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
PCM
Perkins Capital Management Wayzata, Minnesota $107M AUM 82.62% 1-Year Est. Return
SS
Sunbelt Securities Houston, Texas $1.58B AUM 28.96% 1-Year Est. Return

Aberdeen Group's LUCD Position: Q1 2026 in Review

Aberdeen Group increased its Lucid Diagnostics (LUCD) stake by 5.4% in Q1 2026, buying an estimated $237K and bringing the position to 3,644,277 shares worth $4.19M. The position accounts for 0.01% of the portfolio, ranked #707.

Aberdeen Group first reported a position in LUCD in Q3 2025 and has held it in 3 quarters since. 103 funds tracked by Wall St. Rank hold LUCD as of Q1 2026.

  • Aberdeen Group held 3,644,277 shares of Lucid Diagnostics worth $4.19M as of Q1 2026.
  • Aberdeen Group bought 186,383 Lucid Diagnostics shares in Q1 2026, an estimated $237K.
  • Lucid Diagnostics made up 0.01% of Aberdeen Group's portfolio in Q1 2026, its #707 holding.
  • Aberdeen Group first reported a position in Lucid Diagnostics in Q3 2025 and has held it in 3 quarters since.
  • 103 funds tracked by Wall St. Rank held Lucid Diagnostics as of Q1 2026.

Based on Aberdeen Group's 13F filing for Q1 2026, filed 29 Apr 2026.